Evaluation of the PK of NRL972 Following Pre- and co-Administration of Ursodeoxycholic Acid and Cloxacillin

Norgine logo

Norgine

Status and phase

Completed
Phase 1

Conditions

Hepatic Cirrhosis

Treatments

Drug: NRL972

Study type

Interventional

Funder types

Industry

Identifiers

NCT00857480
NRL972-05/2005 (IN-B)

Details and patient eligibility

About

A study in healthy volunteers to determine whether different drugs metabolised by the liver have any effects on how NRL972 is processed within the body.

Enrollment

12 patients

Sex

All

Ages

21 to 40 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Males or females (females of non-childbearing potential or of childbearing potential while taking medically appropriate contraception)
  2. Caucasian
  3. Age: 21 - 40 years
  4. BW 50 - 100 kg
  5. BMI 20 - 26 kg.m-2
  6. healthy based on the pre-study examination
  7. willing and able to provide informed consent

Exclusion criteria

General - all subjects

  1. Previous participation in the trial

  2. Participant in any other trial during the last 90 days

  3. Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months

  4. History of any clinically relevant allergy (including hypersensitivity to the trial medications)

  5. Presence of acute or chronic infection

  6. Presence or history of any relevant co-morbidity

  7. Resting systolic blood pressure > 160 or < 90 mmHg, diastolic blood pressure > 95 or < 50 mmHg

  8. Clinically relevant ECG-abnormalities, prolonged QTc with > 450 msec in males and > 460 msec in females in particular

  9. Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes

  10. Positive serology for HBsAg, anti HBc and anti HCV

  11. Positive HIV test

  12. Positive alcohol or urine drug test on recruitment (and upon admission)

  13. History of alcohol and/or drug abuse and/or daily use of > 30 gr alcohol

  14. Smoking more than 15 cigarettes/day or equivalent of other tobacco products

  15. Use of prohibited medication

  16. Suspicion or evidence that the subject is not trustworthy and reliable

  17. Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard

    General - all females

  18. Positive pregnancy test

  19. Lactating

  20. Not using appropriate contraception in pre-menopausal women (note: under the conditions of the present study, women using hormonal contraceptives will be informed that this method is not sufficient during the study and that further i.e. mechanical methods [condom, diaphragm with spermicidal gel] should be us

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

12 participants in 3 patient groups

Reference
Experimental group
Description:
No pre-treatment
Treatment:
Drug: NRL972
T1
Experimental group
Description:
Cloxacillin pre- and co-treatment
Treatment:
Drug: NRL972
T2
Experimental group
Description:
UDCA pre-treatment
Treatment:
Drug: NRL972

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems